Sign inJoin waitlistJoin the waitlist

Rita Assi

Associate Professor of Clinical Medicine · Indiana University School of Medicine

Credentials: · ·

History

Indiana University School of Medicine
Present

Hematology and Medical Oncology
Indiana University School of Medicine
2019–2022
University of Texas M D Anderson Cancer Center
2016–2019
Doctor of Medicine
2006–2010

Research

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2023 · 188 citations
Appendiceal Mucinous Neoplasms: Diagnosis and Management
Review · The Oncologist · 2017 · 176 citations
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia
Clinical Lymphoma · 2017 · First of 14 authors · 134 citations

Hagop Kantarjian
15 papers
Elias Jabbour
11 papers
Guillermo Garcia-Manero
11 papers
Naval Daver
11 papers
Jorge Cortes
10 papers
Tapan Kadia
10 papers
Courtney DiNardo
7 papers
GB
Gautam Borthakur
7 papers
Keyur Patel
7 papers
Koichi Takahashi
6 papers
Naveen Pemmaraju
6 papers
ZE
Zeev Estrov
6 papers

Clinical trials

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Principal investigator · Recruiting · Phase 2
Rita Assi
2024–2029
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029